Kiora partners with Choroideremia Research Foundation on new treatment for retinal disease
Click Here to Manage Email Alerts
Koira Pharmaceuticals, in a new partnership with the Choroideremia Research Foundation, plans to accelerate its development of KIO-301, a treatment for the rare retinal disease choroideremia.
“This collaboration with Kiora represents a significant step forward in our mission to bring new options to patients living with choroideremia,” Kathi Wagner, executive director of the Choroideremia Research Foundation (CRF), said in a Koira press release. “There is only one other active clinical stage program in [choroideremia], which is simply not enough. We believe that KIO-301 has the potential to make a significant difference in the lives of those affected by this disease.”
According to the release, KIO-301 is a small molecule designed to restore vision in those with late-stage retinal degeneration. The investigational treatment works by selectively entering retinal ganglion cells and converting them to light sensing cells, making it possible to perceive and interpret light.
In partnering with Kiora, CRF will provide access to clinical and scientific thought leaders and will help enroll patients for future trials of KIO-301.
“With the early clinical evidence and understanding of how KIO-301 works, we see a clear path for its application to choroideremia,” Brian Strem, PhD, Kiora’s CEO and president, said in the release. “By joining forces with CRF, we hope to make significant strides in the fight against this disease and accelerate the path to bringing this therapy to all of those in need.”
Reference:
- Kiora Pharmaceuticals receives clinical trial approval for first-in-human evaluation of KIO-301 to restore vision in patients with retinitis pigmentosa https://ir.kiorapharma.com/news-events/press-releases/detail/152/kiora-pharmaceuticals-receives-clinical-trial-approval-for. Published June 27, 2022. Accessed Aug. 22, 2023.
Read more about
Click Here to Manage Email Alerts